Compare Recursion Pharmaceuticals Inc (RXRX) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Walmart Stores Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.25 (market cap $1.86B), while Walmart Stores Inc trades at $106.18 (market cap $841.37B). The key difference: Walmart Stores Inc is far larger — about 452.3× Recursion Pharmaceuticals Inc's market cap, and Walmart Stores Inc pays a 0.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WMT | |
|---|---|---|
Market Cap | $1.86B | $841.37B |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $134.20 |
52-Week Low | $2.84 | $100.41 |
Enterprise Value | $1.38B | $903.60B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Walmart (WMT) trades at $105.83, down 1.22% on the day, amid a bearish technical signal but strong fundamental performance. The company has beaten EPS estimates for three consecutive quarters, with revenue reaching $680.99 billion in 2025 and net income margin improving to 2.85%. Analyst consensus is strongly bullish with a $130.69 price target, though technical indicators show near-term resistance around $107.
The outlook remains positive given consistent earnings beats, expanding profit margins, and strategic initiatives in delivery and AI. Key risks include competitive pressure from Amazon, which recently surpassed Walmart in revenue, and potential margin compression from increased investment. The stock offers a compelling long-term growth story supported by operational efficiency and market dominance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
